Rectal administration of Lactobacillus casei DG modifies flora composition and toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis

Digestive Diseases and Sciences

Volumn 56, Issue 4, 2011, Pages 1178-1187

  D'Incà, Renata ^a   Barollo, Michela ^a   Scarpa, Marco ^b   Grillo, Alessia Rosaria ^a   Brun, Paola ^a   Vettorato, Maria Grazia ^a   Castagliuolo, Ignazio ^a   Sturniolo, Giacomo Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Enema; Lactobacilli; Toll like receptor; Ulcerative colitis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; MESALAZINE; MESSENGER RNA; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON MUCOSA; DISEASE SEVERITY; DRUG EFFECT; ENTEROBACTERIACEAE; HUMAN; LACTOBACILLUS; LACTOBACILLUS CASEI; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLON; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LACTOBACILLUS CASEI; MESALAMINE; PROBIOTICS; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 79955636576     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1384-1     Document Type: Article

References (50)

1. Kelly D, Conway S, Aminov R. Commensal gut bacteria: Mechanisms of immune modulation. Trends Immunol. 2005;26:326-333. (Pubitemid 40732666)
2. Sartor RB. Enteric microflora in IBD: Pathogens or commensal? Inflamm. Bowel Dis. 1997;3:230-235. (Pubitemid 127726448)
3. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VLS#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114. (Pubitemid 38083018)
4. Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209. (Pubitemid 36531796)
5. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: Possible mechanisms of action. Curr Opin Gastroenterol. 2005;21:426-430. (Pubitemid 40961168)
6. White NR, Mulligan P, King PJ, et al. Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatric Gastroenterol Nutr. 2006;42:134-141.
7. Ewaschuk JB, Walker JW, Diaz H, et al. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr. 2006;136:1483-1487. (Pubitemid 43765349)
8. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004;127:777-791. (Pubitemid 39208411)
9. Voltan S, Martines D, Elli M, et al. Lactobacillus crispatus M247-Derived H2O2 Acts as a Signal Transducing Molecule Activating Peroxisome Proliferator Activated Receptor-γ in the Intestinal Mucosa. Gastroenterology. 2008;135:1216-1227.
10. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 2005;54:1182-1193. (Pubitemid 41025918)
11. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: Different Toll-like receptors agonist instruct dendritic cells to induce distinct Th responses via different modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol. 2003;171:4984-4989. (Pubitemid 37432777)
12. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257-263. (Pubitemid 38902439)
13. Netea MG, Van der Meer JWM, Kullberg BJ. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 2004;12:484-488. (Pubitemid 39370729)
14. Voltan S, Castagliuolo I, Elli M, et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin Vaccine Immunol. 2007;14:1138-1148. (Pubitemid 47518080)
15. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132:1359-1374. (Pubitemid 46627595)
16. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010-7017. (Pubitemid 32463415)
17. Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol. 2005;42:887-893. (Pubitemid 40489012)
18. Castagliuolo I, Galeazzi F, Ferrari S, et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol. 2005;43:197-204. (Pubitemid 40170289)
19. Nanda Kumar NS, Balamurugan R, Jayakanthan K, et al. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol. 2008;23:1834-1839.
20. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
21. Baron J, Connell A, Lennard-Jones A. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:189-192.
22. Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987;22:459-462. (Pubitemid 17078540)
23. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in pediatric patients with inflammatory bowel disease. Gut. 2006;55:1760-1767. (Pubitemid 44893575)
24. Rivas R, Zurdo-Piñeiro EV, Mateos PF, et al. Identification of microorganisms by PCR amplification and sequencing of a universal amplified ribosomal region present in both prokaryotes and eukaryotes. J Microbiol Meth. 2004;56:413-426. (Pubitemid 38210346)
25. Mylonaki M, Rayment NB, Rampton DS, et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel diseases. Inflamm Bowel Dis. 2005;11:481-487. (Pubitemid 40704083)
26. Seksik P, Rigottier-Gois L, Gramet G. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003;52:237-242. (Pubitemid 36115065)
27. Penders J, Stobberingh EE, van den Brandt PA, et al. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62:1223-1236. (Pubitemid 47537504)
28. Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut. 2007;56:661-667. (Pubitemid 46662932)
29. Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070-11075. (Pubitemid 41105994)
30. Shiba T, Aiba Y, Ishikawa H, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47:371-378. (Pubitemid 36759441)
31. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137:819S-824S.
32. Gionchetti P, Rizzello F, Heiwug U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209. (Pubitemid 36531796)
33. Kruis W, Fri P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
34. Cui H-H, Chen C-L, Wang J-D, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10:1521-1525. (Pubitemid 39206821)
35. Suau A, Bonnet R, Sutren M, Gordon JJ, Gibson GR, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799-4807.
36. Bartosch S, Fite A, Macfarlane GT, McMurdo MF. Characteization of bacterial communities in feces from healthy volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the faecal microbiota. Appl Environ Microbiol. 2004;70:3575-3581. (Pubitemid 38745906)
37. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut micobiota, as revealed by deep 16S rRNA sequencing. PLOS Biol. 2008,6:e2802383-2400.
38. Morelli L, Garbagna N, Rizzello F, Zonenschain D, Grossi E. In vivo association to human colon of Lactobacillus paracasei B21060: Map from biopsies. Dig Liv Dis. 2006;38:894-898.
39. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412-421. (Pubitemid 39091889)
40. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009;60(Suppl 6):61-71.
41. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001;234:29-40. (Pubitemid 33070909)
42. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108. (Pubitemid 29374113)
43. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004;5:104-112. (Pubitemid 38081475)
44. van Baarlen P, Troost FJ, van Hemert S, et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106:2371-2376.
45. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435. (Pubitemid 34177889)
46. Ortega-Cava CF, Ishihara S, Rumi MAK, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol. 2003;170:3977-3985. (Pubitemid 36428158)
47. Zhang R, Li Y, Beck PL, et al. Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-)) mice. Biochem Soc Trans. 2007;35:1375-1376. (Pubitemid 350206504)
48. Masayuki F, Fukata M, Chen A, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869-1881.
49. Cario E, Gerken G, Podolsky D. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology. 2004;127:224-238. (Pubitemid 38962290)
50. Seo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: Comparisons between a new activity index and Truelove and Witts' classification. Am J Gastroenterol. 1995;90:1759-1763.